May 2008
Volume 49, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2008
Blood Pressure Measurements Following Intravitreal Ranibizumab
Author Affiliations & Notes
  • U. K. Nair
    Ophthalmology, California Pacific Medical Center, San Francisco, California
  • A. Bui
    Ophthalmology, California Pacific Medical Center, San Francisco, California
    West Coast Retina Medical Group, San Francisco, California
  • R. Roe
    Ophthalmology, California Pacific Medical Center, San Francisco, California
    West Coast Retina Medical Group, San Francisco, California
  • A. D. Fu
    Ophthalmology, California Pacific Medical Center, San Francisco, California
    West Coast Retina Medical Group, San Francisco, California
  • J. M. Jumper
    Ophthalmology, California Pacific Medical Center, San Francisco, California
    West Coast Retina Medical Group, San Francisco, California
  • R. N. Johnson
    Ophthalmology, California Pacific Medical Center, San Francisco, California
    West Coast Retina Medical Group, San Francisco, California
  • H. R. McDonald
    Ophthalmology, California Pacific Medical Center, San Francisco, California
    West Coast Retina Medical Group, San Francisco, California
  • E. T. Cunningham, Jr.
    Ophthalmology, California Pacific Medical Center, San Francisco, California
    West Coast Retina Medical Group, San Francisco, California
  • Footnotes
    Commercial Relationships  U.K. Nair, None; A. Bui, None; R. Roe, None; A.D. Fu, None; J.M. Jumper, None; R.N. Johnson, None; H.R. McDonald, None; E.T. Cunningham, None.
  • Footnotes
    Support  None.
Investigative Ophthalmology & Visual Science May 2008, Vol.49, 4577. doi:https://doi.org/
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      U. K. Nair, A. Bui, R. Roe, A. D. Fu, J. M. Jumper, R. N. Johnson, H. R. McDonald, E. T. Cunningham, Jr.; Blood Pressure Measurements Following Intravitreal Ranibizumab. Invest. Ophthalmol. Vis. Sci. 2008;49(13):4577. doi: https://doi.org/.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : To evaluate the effect of intravitreal Ranibizumab on blood pressure in patients with neovascular age-related macular degeneration (AMD).

Methods: : Retrospective chart review was conducted for consecutive patients (n=71) who received intravitreal Ranibizumab to treat neovascular AMD had blood pressure measured prior to intravitreal injection and at monthly follow up visits.

Results: : Follow up ranged from 0 to 10 months, with a mean of 3.4 and a median of 4 months. 63% of patients had a history of systemic hypertension and 4% had a history of stroke prior to receiving Ranibizumab. Average pre-injection systolic, diastolic, and mean arterial blood pressures (MAP) were 132, 73.30, and 92.88 respectively. Average post-injection systolic, diastolic and MAP at one month were 131.80, 71, and 94.95. One patient (1.4%) had a stroke between her second and third visits. Another patient was found to have a pigment epithelial tear. None of these patients experienced a change in blood pressure following their first injection. No other ocular or systemic adverse events were noted.

Conclusions: : Ranibizumab does not appear to affect systemic blood pressure in the short term.

Keywords: vascular endothelial growth factor • choroid: neovascularization • neovascularization 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×